BRAF and metastatic melanoma: To further assess the efficacy of vemurafenib in BM an open label, single arm trial was designed to evaluate the safety and efficacy of the drug in patients with metastatic melanoma with BRAF V600 mutations and nonresectable BM, pretreated with radiotherapy and/or chemotherapy [11].